LTC2245145I2 - Aktyvių gausiai fosforilintų žmogaus lizosominės sulfatazės fermentų gamyba ir panaudojimas - Google Patents

Aktyvių gausiai fosforilintų žmogaus lizosominės sulfatazės fermentų gamyba ir panaudojimas

Info

Publication number
LTC2245145I2
LTC2245145I2 LTPA2017016C LTPA2017016C LTC2245145I2 LT C2245145 I2 LTC2245145 I2 LT C2245145I2 LT PA2017016 C LTPA2017016 C LT PA2017016C LT PA2017016 C LTPA2017016 C LT PA2017016C LT C2245145 I2 LTC2245145 I2 LT C2245145I2
Authority
LT
Lithuania
Prior art keywords
richly
active
production
lysosomal sulfatase
human lysosomal
Prior art date
Application number
LTPA2017016C
Other languages
English (en)
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2245145(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of LTPA2017016I1 publication Critical patent/LTPA2017016I1/lt
Publication of LTC2245145I2 publication Critical patent/LTC2245145I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06014—N-Acetylglucosamine-6-sulfatase (3.1.6.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
LTPA2017016C 2008-01-18 2017-05-25 Aktyvių gausiai fosforilintų žmogaus lizosominės sulfatazės fermentų gamyba ir panaudojimas LTC2245145I2 (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2217908P 2008-01-18 2008-01-18
US9937308P 2008-09-23 2008-09-23
US11024608P 2008-10-31 2008-10-31
PCT/US2009/031276 WO2009091994A2 (en) 2008-01-18 2009-01-16 Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

Publications (2)

Publication Number Publication Date
LTPA2017016I1 LTPA2017016I1 (lt) 2017-06-12
LTC2245145I2 true LTC2245145I2 (lt) 2019-04-25

Family

ID=40451345

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP16203748.5T LT3219795T (lt) 2008-01-18 2009-01-16 Aktyvių, aukšto fosforilinimo lygio žmogaus lizosominės sulfatazės fermentų gamyba ir jų panaudojimas
LTEP09702074.7T LT2245145T (lt) 2008-01-18 2009-01-16 Aktyvių gausiai fosforilintų žmogaus lizosominės sulfatazės fermentų gamyba ir jų panaudojimas
LTPA2017016C LTC2245145I2 (lt) 2008-01-18 2017-05-25 Aktyvių gausiai fosforilintų žmogaus lizosominės sulfatazės fermentų gamyba ir panaudojimas

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LTEP16203748.5T LT3219795T (lt) 2008-01-18 2009-01-16 Aktyvių, aukšto fosforilinimo lygio žmogaus lizosominės sulfatazės fermentų gamyba ir jų panaudojimas
LTEP09702074.7T LT2245145T (lt) 2008-01-18 2009-01-16 Aktyvių gausiai fosforilintų žmogaus lizosominės sulfatazės fermentų gamyba ir jų panaudojimas

Country Status (29)

Country Link
US (7) US8128925B2 (lt)
EP (3) EP4413994A3 (lt)
JP (1) JP5687069B2 (lt)
KR (1) KR101744142B1 (lt)
CN (3) CN102027110A (lt)
AR (1) AR070198A1 (lt)
AU (1) AU2009205978B2 (lt)
BR (1) BRPI0906948B1 (lt)
CA (3) CA3112632C (lt)
CL (1) CL2009000091A1 (lt)
CY (2) CY1118984T1 (lt)
DK (2) DK3219795T3 (lt)
ES (1) ES2984846T3 (lt)
FI (1) FI3219795T3 (lt)
HR (2) HRP20240732T3 (lt)
HU (3) HUE032074T2 (lt)
IL (1) IL206975A (lt)
LT (3) LT3219795T (lt)
MX (1) MX2010007846A (lt)
NL (1) NL300874I2 (lt)
NO (1) NO2017024I1 (lt)
PE (2) PE20140841A1 (lt)
PL (2) PL3219795T3 (lt)
PT (2) PT3219795T (lt)
RU (1) RU2510820C2 (lt)
SI (2) SI2245145T1 (lt)
TW (1) TWI395816B (lt)
WO (1) WO2009091994A2 (lt)
ZA (1) ZA201004674B (lt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5967861B2 (ja) 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド 分子のグリコシル化
PL3219795T3 (pl) * 2008-01-18 2024-09-16 Biomarin Pharmaceutical Inc. Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania
KR102000383B1 (ko) 2009-09-29 2019-07-15 유니버시테이트 젠트 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
US20130053550A1 (en) 2009-11-19 2013-02-28 Oxyrane Uk Limited Yeast strains producing mammalian-like complex n-glycans
BR112012033214B1 (pt) 2010-06-25 2020-11-03 Shire Human Genetic Therapies, Inc. uso de uma formulação estável compreendendo uma proteína de iduronato-2-sulfatase (i2s), formulação compreendendo a mesma e recipiente
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
BR112013007616B1 (pt) 2010-09-29 2023-01-24 Oxyrane Uk Limited Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero
JP6131190B2 (ja) 2010-09-29 2017-05-17 オキシレイン ユーケー リミテッド リン酸化ｎ−グリカンの脱マンノシル化
KR101535791B1 (ko) * 2010-11-12 2015-07-10 주식회사 녹십자 개량형 이듀로네이트-2-설파타제 및 이의 용도
US9206401B2 (en) * 2010-12-22 2015-12-08 Fondazione Telethon Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
TW201307563A (zh) 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素－ｎ－硫酸酯酶之方法
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
CA2867237C (en) 2012-03-15 2024-01-02 Wouter Vervecken Methods and materials for treatment of pompe's disease
WO2013148323A1 (en) * 2012-03-30 2013-10-03 Shire Human Genetic Therapies Methods of analyzing and preparing protein compositions
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
PL2920198T3 (pl) * 2012-11-13 2020-03-31 Chiesi Farmaceutici S.P.A. Oczyszczanie rekombinowanej ludzkiej beta-galaktozydazy galaktocerebrozydowej (rhgalc)
US20190040368A1 (en) * 2013-03-05 2019-02-07 Oxyrane Uk Limited Production of catalytically active type i sulfatase
EA201691393A1 (ru) * 2014-02-18 2016-12-30 Шир Хьюман Дженетик Терапис, Инк. Методы анализа клиренса субстрата для лизосомальных ферментов
SMT201800511T1 (it) * 2014-04-01 2018-11-09 Swedish Orphan Biovitrum Ab Publ Sulfamidasi modificata e sua produzione
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
HK1253529A1 (zh) 2015-11-06 2019-06-21 Biomarin Pharmaceutical Inc. 用於检测中和溶酶体酶的摄取的抗体或其它因子的基於细胞的测定
RU2673038C2 (ru) * 2016-01-18 2018-11-21 ООО "Международный Биотехнологический Центр "Генериум" Лекарственное средство на основе бифункционального антитела для лечения мукополисахаридоза II типа
JP6430980B2 (ja) * 2016-03-09 2018-11-28 フォンダッツィオーネ・テレソン ムコ多糖症におけるｃｎｓ病変を処置するための治療戦略
CN111065735B (zh) * 2017-08-31 2023-07-07 株式会社绿十字 用于纯化硫酸酯酶蛋白的方法
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
EP3963073A4 (en) 2019-04-29 2023-01-25 The University of North Carolina at Chapel Hill OPTIMIZED SUMF1 GENES AND EXPRESSION CASSETTE AND THEIR USE
RU2763990C2 (ru) * 2020-02-19 2022-01-12 Акционерное общество "ГЕНЕРИУМ" Клетка, продуцирующая с высокой эффективностью активный белок арилсульфатазу в, и способ получения этой клетки
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
CA3228179A1 (en) * 2021-08-18 2023-02-23 Joint-Stock Company "Generium" Targeted delivery of therapeutic enzymes

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US7083793B2 (en) * 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
US6534300B1 (en) * 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US6972124B2 (en) 2000-05-01 2005-12-06 Biomarin Pharmaceuticals Inc. Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
AUPS293002A0 (en) 2002-06-14 2002-07-04 Women's And Children's Hospital Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
CN110496230A (zh) * 2003-02-11 2019-11-26 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
NZ576986A (en) * 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
US20080014188A1 (en) * 2004-02-06 2008-01-17 Zankel Todd C Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof
WO2005113765A2 (en) * 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
US7863238B2 (en) * 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
US7932032B2 (en) 2005-05-02 2011-04-26 Toray Industries, Inc. Method for diagnosing esophageal cancer
EP1818395A1 (en) 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
JP2010515434A (ja) 2007-01-05 2010-05-13 マサチューセッツ インスティテュート オブ テクノロジー Ｆｌａｖｏｂａｃｔｅｒｉｕｍｈｅｐａｒｉｎｕｍ由来のスルファターゼを使用する組成物および方法
WO2009034159A1 (en) 2007-09-12 2009-03-19 Vivendy Therapeutics Ltd: Short polypeptide mediated conformational changes promoting enhancement of enzymatic activity
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
PL3219795T3 (pl) 2008-01-18 2024-09-16 Biomarin Pharmaceutical Inc. Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos

Also Published As

Publication number Publication date
CA2711590C (en) 2021-03-23
EP4413994A2 (en) 2024-08-14
AU2009205978B2 (en) 2014-04-10
US9200264B2 (en) 2015-12-01
US20120208221A1 (en) 2012-08-16
US8420368B2 (en) 2013-04-16
NO2017024I1 (no) 2017-05-30
LT2245145T (lt) 2017-04-10
LT3219795T (lt) 2024-07-25
JP5687069B2 (ja) 2015-03-18
CA3295047A1 (en) 2026-03-02
US8128925B2 (en) 2012-03-06
CY1118984T1 (el) 2017-11-14
AU2009205978A1 (en) 2009-07-23
WO2009091994A2 (en) 2009-07-23
RU2010134412A (ru) 2012-02-27
BRPI0906948B1 (pt) 2023-05-16
DK3219795T3 (da) 2024-06-17
PT2245145T (pt) 2017-03-14
PL2245145T3 (pl) 2017-07-31
TWI395816B (zh) 2013-05-11
CN102027110A (zh) 2011-04-20
KR101744142B1 (ko) 2017-06-07
CA2711590A1 (en) 2009-07-23
US20210189357A1 (en) 2021-06-24
EP3219795B1 (en) 2024-03-13
EP2245145A2 (en) 2010-11-03
PL3219795T3 (pl) 2024-09-16
US10563183B2 (en) 2020-02-18
CA3112632A1 (en) 2009-07-23
PE20140841A1 (es) 2014-08-03
JP2011509674A (ja) 2011-03-31
PT3219795T (pt) 2024-06-18
TW200934869A (en) 2009-08-16
HUE032074T2 (en) 2017-08-28
NL300874I2 (nl) 2018-04-12
KR20100108438A (ko) 2010-10-06
FI3219795T3 (fi) 2024-06-12
WO2009091994A3 (en) 2009-10-29
IL206975A (en) 2013-06-27
DK2245145T3 (en) 2017-03-20
CY2017018I2 (el) 2017-11-14
LTPA2017016I1 (lt) 2017-06-12
AR070198A1 (es) 2010-03-17
HRP20240732T3 (hr) 2024-08-30
HRP20170366T1 (hr) 2017-05-05
CA3112632C (en) 2026-05-12
ZA201004674B (en) 2011-09-28
US20180208913A1 (en) 2018-07-26
WO2009091994A9 (en) 2009-12-03
US12188058B2 (en) 2025-01-07
EP3219795A1 (en) 2017-09-20
BRPI0906948A2 (pt) 2015-07-14
US9873867B2 (en) 2018-01-23
HK1244505A1 (en) 2018-08-10
RU2510820C2 (ru) 2014-04-10
US10934534B2 (en) 2021-03-02
HUE066911T2 (hu) 2024-09-28
SI3219795T1 (sl) 2024-10-30
US20160201039A1 (en) 2016-07-14
IL206975A0 (en) 2010-12-30
PE20091319A1 (es) 2009-09-23
ES2984846T3 (es) 2024-10-31
CY2017018I1 (el) 2017-11-14
CN105274072A (zh) 2016-01-27
MX2010007846A (es) 2010-10-05
US20200181590A1 (en) 2020-06-11
SI2245145T1 (sl) 2017-05-31
US20090186011A1 (en) 2009-07-23
HUS1700022I1 (hu) 2017-06-28
EP2245145B1 (en) 2016-12-14
CN121109347A (zh) 2025-12-12
CL2009000091A1 (es) 2009-03-27
EP4413994A3 (en) 2024-12-18
US20130236921A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
LTPA2017016I1 (lt) Aktyvių gausiai fosforilintų žmogaus lizosominės sulfatazės fermentų gamyba ir panaudojimas
IL260282B (en) Human acetylgalactosamine-6-sulfatase-n production of highly active phosphorylated and its uses
EP2561069A4 (en) ENZYM FOR LYSOSOMAL STORAGE DISEASE
IL240098A (en) Disinfectant containing digestive enzymes
EP2155197A4 (en) TREATMENT OF LYSOSOMAL STORAGE DISEASES
IL245283B (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
PL3050571T3 (pl) Preparat enzymu trawiennego do leczenia rzucawki
BRPI0810480A2 (pt) Variantes da enzima asparaginase e usos das mesmas
EP2356446A4 (en) Therapeutic and diagnostic methods related to cancer stem cells
ZA201109367B (en) Combinations of fungicidally active yeast and fungicides
ZA201204066B (en) Hatching fluid enzymes and uses thereof
BRPI0924839A2 (pt) combinações de substâncias ativas com propriedades inseticidas e acaricidas
EP2408907B8 (en) Use of cellulose and ligno-cellulose active proteins
FIU20100152U0 (fi) Saunan kiukaan runko ja sen rakenne
PY1126135A (es) Entrega intratecal de enzimas lisosomales y usos terapéuticos de las mismas
PL387593A1 (pl) Szkło-ceramika optycznie aktywna i sposób otrzymywania szkło-ceramiki optycznie aktywnej
PL385093A1 (pl) Sposób otrzymywania nierozpuszczalnych preparatów enzymów katalizujących hydrolizę chitozanu